Study of Methotrexate Given to Juvenile Idiopathic Arthritis Patients Based on Pharmacogenomics and Pharmacometrics
NCT ID: NCT03006991
Last Updated: 2016-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2016-11-30
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
good efficacy
using therapeutic drug monitoring to adjust the dose of methotrexate. patients can reach effective outcome.
therapeutic drug monitoring
dose of methotrexate can be adjusted by therapeutic drug monitoring.
poor efficacy
patients can not reach effective outcome.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
therapeutic drug monitoring
dose of methotrexate can be adjusted by therapeutic drug monitoring.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 7.5-10mg/m2 per week per dose of methotrexate
* all patients have been treated with methotrexate at least for 3 months
Exclusion Criteria
1 Month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou Women and Children's Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mo Xiaolan
Mo Xiaolan
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaolan Mo, master
Role: PRINCIPAL_INVESTIGATOR
Guangzhou Women and Children's Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangzhou Women and Children's Medical Center
Guandong, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Huasong Zeng, Doctor
Role: primary
Hongwei Li, Master
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Yanagimachi M, Naruto T, Hara T, Kikuchi M, Hara R, Miyamae T, Imagawa T, Mori M, Kaneko T, Morita S, Goto H, Yokota S. Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. Br J Clin Pharmacol. 2011 Feb;71(2):237-43. doi: 10.1111/j.1365-2125.2010.03814.x.
Related Links
Access external resources that provide additional context or updates about the study.
Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
81603203
Identifier Type: -
Identifier Source: org_study_id